Bolt Biotherapeutics CEO William P. Quinn Sells Shares

What Happened

• William P. Quinn, President, CEO, CFO and a director of Bolt Biotherapeutics (BOLT), reported both a small purchase and multiple sales. He acquired 637 shares on 2026-06-05 at $3.88 each for $2,469 (purchase). He sold 1,889 shares on 2026-09-16 at $3.77 ($7,129), 6,545 shares on 2026-09-17 at $3.32 ($21,718), and 9,132 shares on 2026-09-18 at $3.24 ($29,555) — total sales = 17,566 shares for $58,402. Overall this filing shows net disposition (sales exceeded purchases) of roughly $55.9K.

Key Details

• Transaction dates & reported prices:
  • 2026-06-05: Purchase (P) — 637 sh @ $3.88 = $2,469 (ESPP purchase; exempt under Rule 16b-3(c)) [F1]
  • 2026-09-16: Sale (S) — 1,889 sh @ $3.77 = $7,129 (weighted avg; range $3.60–$4.14) [F2]
  • 2026-09-17: Sale (S) — 6,545 sh @ $3.32 = $21,718 (weighted avg; range $3.22–$3.67) [F3]
  • 2026-09-18: Sale (S) — 9,132 sh @ $3.24 = $29,555 (weighted avg; range $3.15–$3.41) [F4]
• Purpose of sales: Footnotes F2–F4 state the September sales were to cover tax withholding for restricted stock units that vested (granted Oct 22, 2025). Weighted-average prices reported; exact per-price breakdown available from the filer on request.
• Shares owned after the transactions: Not specified in the excerpt provided — see the full Form 4 for post-transaction holdings.
• Filing info/timeliness: Form 4 filed with the SEC on 2026-09-21 (reporting activity through 2026-09-18). No late-filing flag is indicated in the provided data.

Context

• These sales were reported as tax-withholding transactions tied to RSU vesting, which are routine and do not necessarily indicate a change in insider sentiment. The June purchase was via the company Employee Stock Purchase Plan (ESP), a routine, generally bullish signal though small in size here. No options exercises, gifts, or 10%‑owner transactions are indicated in this filing.